Pexidartinib
- Generic Name
- Pexidartinib
- Brand Names
- Turalio
- Drug Type
- Small Molecule
- Chemical Formula
- C20H15ClF3N5
- CAS Number
- 1029044-16-3
- Unique Ingredient Identifier
- 6783M2LV5X
- Background
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial gia...
- Indication
Pexidartinib is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
- Associated Conditions
- Symptomatic Tenosynovial Giant Cell Tumor
- Associated Therapies
- -
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
- Conditions
- Interventions
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 120
- Registration Number
- NCT02371369
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇫🇷Institut Gustave Roussy, Villejuif, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.